Generate Biomedicines, Inc.
Pharmaceutical Preparations
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
What Generate Biomedicines, Inc. reports
Why the revenue box is blank
US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.
Where the employee count comes from
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at Generate Biomedicines, Inc.
Shares is what each person last reported holding here.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Officers 1 | ||||
Gevorg Grigoryan
|
CTO | 659,973 | $10.82M | — position reported |
| Officers who also sit on the board 2 | ||||
Michael Nally
|
CEO | 2,889,154 | $47.35M | P Open-market purchase Mar 4, 2026 position reported |
| Stephane Bancel | CEO | 1,184,989 | $19.42M | C Conversion of derivative Mar 2, 2026 position reported |
| Directors 1 | ||||
Frances Arnold
|
Board Member | 464,944 | $7.62M | S Open-market sale Sep 1, 2026 position reported |
Recent insider transactions
Of the 4 rows we hold, 1 are open-market purchases (P) and 1 open-market sales (S) — the only codes we count as buying or selling.
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Frances Arnold | S Open-market sale | 1,000 | $16.00 | $16.0K | SEC filing ↗ |
| Mar 4, 2026 | Michael Nally | P Open-market purchase | 20,000 | $12.00 | $240.0K | SEC filing ↗ |
| Mar 2, 2026 | Michael Nally | C Conversion of derivative | 658,327 | $0.00 | $0 | SEC filing ↗ |
| Mar 2, 2026 | Stephane Bancel | C Conversion of derivative | 724,160 | $0.00 | $0 | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
What a Form 4 is
The report an officer, director or large shareholder must file after trading their own company’s stock.
Corporate ownership links — 14 filers hold a position
Who owns Generate Biomedicines, Inc.
Each row is one filer naming this company.
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Do not add these figures together. 13 of the positions below were reported on filings shared by several filers at once.
Why the same shares appear twice
On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.
Filers holding a position in Generate Biomedicines, Inc.
| Owner | Reported role | Shares | Filed |
|---|---|---|---|
| Flagship Pioneering Fund VI General Partner LLC | TenPercentOwner | 62,673,117 joint | |
| Flagship Pioneering Fund VI, L.P. | TenPercentOwner | 62,673,117 joint | |
| Flagship Pioneering Fund VII General Partner LLC | Director,TenPercentOwner | 62,673,117 joint | |
| Flagship Pioneering Fund VII, L.P. | Director,TenPercentOwner | 62,673,117 joint | |
| Flagship Pioneering Special Opportunities Fund II General Partner LLC | Director,TenPercentOwner | 62,673,117 joint | |
| Flagship Pioneering Special Opportunities Fund II, L.P. | Director,TenPercentOwner | 62,673,117 joint | |
| Flagship Pioneering, LLC | Director,TenPercentOwner | 62,673,117 joint | |
| Flagship VentureLabs VI LLC | TenPercentOwner | 62,673,117 joint | |
| Flagship VentureLabs VI Manager LLC | TenPercentOwner | 62,673,117 joint | |
| FPN General Partner LLC | TenPercentOwner | 62,673,117 joint | |
| FPN II, L.P. | TenPercentOwner | 62,673,117 joint | |
| Nutritional Health LTP Fund General Partner LLC | TenPercentOwner | 62,673,117 joint | |
| Nutritional Health LTP Fund, L.P. | TenPercentOwner | 62,673,117 joint | |
| Pioneering Medicines 02, LLC | TenPercentOwner | 1,562,500 |
See the full ownership map — every entity that files as an owner of a US public company.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
Generate Biomedicines, Inc.’s own filings and multiplied by our closing price.
Full method.
What that share count means
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Generate Biomedicines, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.